int-787
·Code: INT-787
int-787: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) | Phase 2 |
Clinical Trials (1)
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis
Frequently asked questions
Who is developing int-787?
int-787 is being developed by INTERCEPT PHARMACEUTICALS, INC..
How many clinical trials involve int-787?
BioSniper tracks 1 clinical trial involving int-787.
Get deeper analysis on int-787
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis